Amgen stock gains on Novo Nordisk's weightloss drug blunder

Amgen stock gains on drug results of Novo Nordisk.
Novo Nordisk's CagriSema drug reduced testings subjects' weight less than expected.
Amgen itself has struggled with developing its MariTide weightloss drug.
AMGN stock has been in a downtrend since at least July.

Clay Webster FXStreet

Amgen stock gained more than 2% in Friday’s morning session after foreign weightloss drug competitor Novo Nordisk (NVO) plunged following the results of new drug testing. As one of the leaders in weightloss pharmaceuticals, the news led other pharma stocks to run higher.

The Dow Jones Industrial Average (DJIA) index surged 1.8%, its best outing in awhile and especially after its historic ten-session pullback ended on Thursday by a hair. The DJIA is leading the NASDAQ and S&P 500 moderately at the time of writing.

The US Personal Consumption Expenditures (PCE) report for November is also cheering stock investors after Wednesday and Thursday witnessed widespread negativity over the Fed’s hawkish outlook. US inflation in the PCE arrived lower than economists had projected, which may mean that the Fed’s worries over inflation are likely to clear up in subsequent reports.

Amgen stock news

Novo Nordisk, the Danish maker of the Wegovy and Ozempic weightloss drugs, released data on the third phase of testing for its new CagriSema drug. CagriSema is supposed to be its next-generation drug for weightloss.

However, the data showed that CagriSema caused users to lose 20% of their weight after 68 weeks. This was in line with existing weightloss medicines and well below the 25% guidance that Novo Nordisk had previously aimed for.

Eli Lilly’s (LLY) Zepbound already reduces weight among its users by 23%, according to similar testing. Since the weightloss drug industry is expected to grow to $150 billion annually by 2030, the competitive nature of the sector has pushed up the competitors to Novo Nordisk.

One of those competitors is Amgen, which has been testing the MariTide drug for the same purpose. The company released test results in late November that showed the drug caused weight loss of up to 20% in obese and overweight individuals over a 52-week period. However, the results also showed that it might be causing patients to lose bone mineral density.

Amgen stock forecast

Amgen’s Thursday low of $253.30 was its lowest price since October 31, 2023, but the pharma stock rode an afternoon wave of optimism to produce a near 1% gain by the close. Friday is confirmation that the mood has changed.

Shares have risen back above the $261 level that acted as support on a number of occasions in late 2023 and throughout 2024. If AMGN stock can retain this region above $261, then the worst may be over. Shares of the pharmaceutical corporation have been trending lower since achieving an all-time high in July of this year above $346.

Still, lows created on November 26 and December 19 below $261 lead us to believe that the bottom may not be in. A third break below $261 will have many traders expecting the stock to dump all the way to the May through July 2023 lows in the demand zone stretching from $211 to $218.

AMGN daily stock chart

Author

Clay Webster

FXStreet

Clay Webster grew up in the US outside Buffalo, New York and Lancaster, Pennsylvania. He began investing after college following the 2008 financial crisis.

AUD/USD remains below 0.7000 amid light trading

AUD/USD fills a modest bearish gap on Monday, but remains below 0.7000 in the Asian session amid holiday-thinned liquidity. The US Dollar attempts a bounce even as US bond yields pull back from multi-year highs, limiting the pair. Moreover, diminishing odds of another RBA rate hike in November cap the Aussie.

USD/JPY hovers above 158.00 amid Japan/ US holiday

USD/JPY extends its range-bound price action into a new week, trading above 158.00 as bulls remain on high alert amid speculation that authorities will step in to prop up the Japanese Yen. Meanwhile, softer US bond yields keep US Dollar bulls on the back foot and cap the pair's upside. However, geopolitical uncertainties could limit losses for the safe-haven buck amid thin liquidity due to a holiday in Japan and the US.

Gold eases from one-week top, falls below $4,200 as hawkish Fed and Iran risks support USD

Gold attracts some sellers after touching a one-week high earlier this Monday, sliding back below the $4,200 mark during the European session and snapping a two-day winning streak. The US Federal Reserve's hawkish outlook helps limit the downside for the US Dollar, and caps the non-yielding bullion. Meanwhile, crude oil prices fell amid hopes that the Russia-Ukraine energy ceasefire deal will ease global fuel shortages and, in turn, reduce inflationary risks.

Cardano holds above EMAs as recovery builds

Cardano (ADA) reclaims trading above the key support zone on Monday after a 2.85% correction last week. Improving derivatives positioning and constructive technical outlook support a recovery for ADA. Derivatives data shows an improving sentiment among Cardano traders. CoinGlass’ long-to-short ratio for ADA reads 1.01 on Monday, flipping into green territory.

USD/INR: Deep in red below 96.00 as RBI rescues Indian Rupee

After opening significantly higher against the US Dollar (USD) on Monday, the Indian Rupee (INR) clings to recovery gains near 95.80. The pair remains undermined by the Reserve Bank of India’s (RBI) fresh measures to curb US Dollar demand, which has brought relief for the Indian currency.

Has Bitcoin really escaped the macro forces it was built to fight?

Over 17 years ago, Satoshi Nakamoto designed Bitcoin (BTC) on the back of a global financial crisis as an alternative to the global monetary system outside the control of central banks, governments and traditional intermediaries. This raises a key question: has Bitcoin really become independent of the macroeconomic forces it was built to challenge?